Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 6/20 | 0.57 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | USP14 | P54578 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2538152 | 0.94 | NPC1L1 (0.55) | NPC1L1KCNA3NAMPTCKS1BSKP1 | |
| SCHEMBL2382030 | 0.79 | DDR1 (0.46) | KMT2AKDM1AMAPK8 | |
| SCHEMBL2309756 | 0.78 | OPRM1 (0.41) | KMT2AKDM1A | |
| SCHEMBL2307089 | 0.77 | TDP1 (0.38) | NPC1L1KMT2A | |
| SCHEMBL2311243 | 0.76 | LMNA (0.52) | KMT2A | |
| SCHEMBL6299819 | 0.75 | KCNA3 (0.53) | NPC1L1KCNA3NAMPTCKS1BSKP1 | |
| SCHEMBL2379745 | 0.74 | NPC1L1 (0.46) | NPC1L1 | |
| SCHEMBL2310823 | 0.74 | OPRM1 (0.49) | KMT2A | |
| SCHEMBL2312529 | 0.73 | TEAD1 (0.54) | KMT2AEPHX2 | |
| SCHEMBL6369365 | 0.72 | NAMPT (0.46) | NPC1L1KCNA3NAMPTCKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | NPC1L1 1304/4885KCNA3 164/4885NAMPT 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.